Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR
Open Access
- 1 July 2019
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 317 (1) , L71-L86
Abstract
Cross-species comparative studies have highlighted differences between human and mouse cystic fibrosis transmembrane conductance regulator (CFTR), the epithelial Cl−channel defective in cystic fibrosis (CF). Here, we compare the impact of the most common CF mutation F508del on the function of human and mouse CFTR heterologously expressed in mammalian cells and their response to CFTR modulators using the iodide efflux and patch-clamp techniques. Once delivered to the plasma membrane, human F508del-CFTR exhibited a severe gating defect characterized by infrequent channel openings and was thermally unstable, deactivating within minutes at 37°C. By contrast, the F508del mutation was without effect on the gating pattern of mouse CFTR, and channel activity demonstrated thermostability at 37°C. Strikingly, at all concentrations tested, the clinically approved CFTR potentiator ivacaftor was without effect on the mouse F508del-CFTR Cl−channel. Moreover, eight CFTR potentiators, including ivacaftor, failed to generate CFTR-mediated iodide efflux from CHO cells expressing mouse F508del-CFTR. However, they all produced CFTR-mediated iodide efflux with human F508del-CFTR-expressing CHO cells, while fifteen CFTR correctors rescued the plasma membrane expression of both human and mouse F508del-CFTR. Interestingly, the CFTR potentiator genistein enhanced CFTR-mediated iodide efflux from CHO cells expressing either human or mouse F508del-CFTR, whereas it only potentiated human F508del-CFTR Cl−channels in cell-free membrane patches, suggesting that its action on mouse F508del-CFTR is indirect. Thus, the F508del mutation has distinct effects on human and mouse CFTR Cl−channels.Keywords
Funding Information
- Cystic Fibrosis Foundation (CFF) (DEJONG04G0)
- Cystic Fibrosis Trust (SRC005 and SRC011)
- Medical Research Council (MRC) (MR/L015919/1)
This publication has 94 references indexed in Scilit:
- Correction of Both NBD1 Energetics and Domain Interface Is Required to Restore ΔF508 CFTR Folding and FunctionCell, 2012
- Requirements for Efficient Correction of ΔF508 CFTR Revealed by Analyses of Evolved SequencesCell, 2012
- ΔF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayersPulmonary Pharmacology & Therapeutics, 2010
- Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosisNature Chemical Biology, 2009
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences, 2009
- 4′-Methyl-4,5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processingBioorganic & Medicinal Chemistry Letters, 2008
- Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulatorBritish Journal of Pharmacology, 2008
- Chimeric constructs endow the human CFTR Cl − channel with the gating behavior of murine CFTRProceedings of the National Academy of Sciences, 2007
- Processing and function of CFTR-ΔF508 are species-dependentProceedings of the National Academy of Sciences, 2007
- Inhibition of CFTR Cl − channel function caused by enzymatic hydrolysis of sphingomyelinProceedings of the National Academy of Sciences, 2007